NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.

NexImmune, Inc.

NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) technology.  NexImmune has a differentiated platform and pipeline of product candidates in pre-clinical and phase 1/2 stages with lead programs focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune’s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities.  For the last decade, the AIM platform has evolved into a stable platform for various therapy targets providing an opportunity to make a massive impact due to its adaptability and flexibility in oncology, autoimmune disorders, infectious disease, and beyond. 

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	5.24M -	5.71M 8.96%	10.01M 75.23%	15.80M 57.80%	15.93M 0.85%	13.00B 81,488.21%
selling general and administrative expenses	5.24M -	5.71M 8.96%	10.01M 75.23%	15.80M 57.80%	15.93M 0.85%	13.00B 81,488.21%
research and development expenses	8.00M -	15.17M 89.68%	17.84M 17.58%	37.46M 109.97%	47.15M 25.88%	19.28B 40,796.85%
other expenses	136.79K -	92.28K 32.54%	89.78K 2.71%	-61.41K 168.40%	-87.68K 42.79%	690.77M 787,910.50%
cost and expenses	13.24M -	20.89M 57.71%	27.85M 33.35%	53.26M 91.21%	63.08M 18.45%	32.97B 52,170.31%
operating expenses	13.24M -	20.89M 57.71%	27.85M 33.35%	53.26M 91.21%	63.08M 18.45%	32.97B 52,170.31%
interest expense			1.68M -	905.33K 46.20%	-576.69M 63,799.71%
ebitda	-13.04M -	-20.45M 56.84%	-27.12M 32.63%	-52.39M 93.18%	-62.51M 19.30%	-32.97B 52,652.56%
operating income	-13.24M -	-20.89M 57.71%	-27.85M 33.35%	-53.26M 91.21%	-63.08M 18.45%	-32.97B 52,170.31%
depreciation and amortization	204.65K -	436.37K 113.23%	729.60K 67.20%	861.39K 18.06%	576.69K 33.05%
total other income expenses net	136.79K -	339.06K 147.87%	-2.01M 694.17%	2.35M 216.86%	576.69K 75.50%	629.23M 109,010.44%
income before tax	-12.83M -	-20.55M 60.10%	-29.87M 45.36%	-50.90M 70.43%	-62.51M 22.80%	-32.34B 51,645.90%
income tax expense	409.22K -	-246.78K 160.30%	1.77M 818.32%	843.92K 52.39%	-576.69M 68,434.76%
net income	-12.83M -	-20.30M 58.18%	-31.64M 55.86%	-51.75M 63.55%	514.18M 1,093.68%	-32.34B 6,390.43%
weighted average shs out	9.77M -	12.93M 32.31%	19.77M 52.92%	20.19M 2.12%	24.06M 19.19%	1.05B 4,262.04%
weighted average shs out dil	9.77M -	12.93M 32.31%	19.77M 52.92%	20.19M 2.12%	24.06M 19.19%	1.05B 4,262.04%
eps	-1.31 -	-1.57 19.85%	-1.60 1.91%	-2.56 60%	21.37 934.77%	-30.82 244.22%
epsdiluted	-1.31 -	-1.57 19.85%	-1.60 1.91%	-2.56 60%	21.37 934.77%	-30.82 244.22%

COM:NEXIMMUNE

NexImmune

Last Close

0.22

21/11 20:00

Market Cap

3.17M

Beta: -

Volume Today

60

Avg: -

Preview